Literature DB >> 3002020

Detection of visna virus antigens and RNA in glial cells in foci of demyelination.

L Stowring, A T Haase, G Petursson, G Georgsson, P Palsson, R Lutley, R Roos, S Szuchet.   

Abstract

Visna is a slow virus infection of sheep in which the characteristic pathological change is demyelination in foci of inflammation. The latter is thought to be the result of an immunopathological process directed against cellular and antigenic targets that have been difficult to define because of restricted viral gene expression. A new simultaneous detection assay is used to demonstrate viral RNA in cells identified unambiguously as oligodendrocytes and astrocytes. These cells were found in inflammatory foci. With a new strain of virus that causes a rapid form of visna in Icelandic sheep, viral antigens were demonstrated in cells in the inflammatory lesions. These findings are consistent with the postulated immunopathological mechanism of demyelination: cells that maintain intact myelin sheaths in the central nervous system are destroyed by the inflammatory response to viral antigens expressed in these cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3002020     DOI: 10.1016/0042-6822(85)90264-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

1.  The widening spectrum of infectious neurological disease.

Authors:  P G Kennedy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

2.  Replication and cytopathic effects of ovine lentivirus strains in alveolar macrophages correlate with in vivo pathogenicity.

Authors:  M D Lairmore; G Y Akita; H I Russell; J C DeMartini
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Scrapie prion proteins are synthesized in neurons.

Authors:  H A Kretzschmar; S B Prusiner; L E Stowring; S J DeArmond
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

4.  Lentivirus-induced lymphoproliferative disease. Comparative pathogenicity of phenotypically distinct ovine lentivirus strains.

Authors:  M D Lairmore; J M Poulson; T A Adducci; J C DeMartini
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

Review 5.  Doxycycline-inducible and astrocyte-specific HIV-1 Tat transgenic mice (iTat) as an HIV/neuroAIDS model.

Authors:  Dianne Langford; Byung Oh Kim; Wei Zou; Yan Fan; Pejman Rahimain; Ying Liu; Johnny J He
Journal:  J Neurovirol       Date:  2017-11-15       Impact factor: 2.643

6.  The maedi-visna virus Tat protein induces multiorgan lymphoid hyperplasia in transgenic mice.

Authors:  C Vellutini; V Philippon; D Gambarelli; N Horschowski; K A Nave; J M Navarro; M Auphan; M A Courcoul; P Filippi
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Human immunodeficiency virus (HIV)-related chronic relapsing inflammatory demyelinating polyneuropathy with multifocal unusual onion bulbs in sural nerve biopsy. A clinicomorphological study with qualitative and quantitative light and electron microscopy.

Authors:  E Gibbels; N Diederich
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

8.  Distribution of a macaque immunosuppressive type D retrovirus in neural, lymphoid, and salivary tissues.

Authors:  A A Lackner; M H Rodriguez; C E Bush; R J Munn; H S Kwang; P F Moore; K G Osborn; P A Marx; M B Gardner; L J Lowenstine
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  Ovine lentivirus is macrophagetropic and does not replicate productively in T lymphocytes.

Authors:  M D Gorrell; M R Brandon; D Sheffer; R J Adams; O Narayan
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Biological and genetic differences between lung- and brain-derived isolates of maedi-visna virus.

Authors:  V Andrésdóttir; X Tang; G Agnarsdóttir; O S Andrésson; G Georgsson; R Skraban; S Torsteinsdóttir; B Rafnar; E Benediktsdóttir; S Matthíasdóttir; S Arnadóttir; S Högnadóttir; P A Pálsson; G Pétursson
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.